Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxFinal Data From Phase 3 PSMAfore Trial About 177Lu-PSMA-617 (Pluvicto)
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026